Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled,Single Dose, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of JPI-289 in Healthy Male Subjects.

Next Previous
Trial Profile

A Phase I Clinical Study, Randomized, Double-blind, Placebo-controlled,Single Dose, Dose Escalation Study of the Safety, Tolerability and Pharmacokinetics of JPI-289 in Healthy Male Subjects.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2019

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amelparib (Primary)
  • Indications Stroke
  • Focus Adverse reactions; First in man
  • Sponsors Jeil Pharmaceutical

Most Recent Events

  • 27 Jun 2017 Results of this and other phase I study presented at the 13th Congress of the European Association for Clinical Pharmacology and Therapeutics.
  • 11 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 12 Feb 2014 Planned End Date changed from 1 Jun 2014 to 1 Sep 2014 according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top